c-MET Proteins, Antibodies, cDNA Clones, ELISA Kits Research Reagents

MET (MET Proto-Oncogene, Receptor Tyrosine Kinase, also known as HGFR; AUTS9; RCCP2; c-Met; DFNB97), located on 7q31.2, is conserved in chimpanzee, Rhesus monkey, dog, cow, mouse, rat, chicken, zebrafish, and frog. The gene produces a 155541 Da protein composed of 1390 amino acids. This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. Diseases such as Renal Cell Carcinoma, Papillary, 1 and Deafness, Autosomal Recessive 97 are associated with MET. The related pathways of MET include Transcriptional misregulation in cancer and RET signaling.

c-MET Protein (14)

c-MET Antibody (24)

    c-MET ELISA キット(すぐに使用できます)& ELISA抗体ペアセット(すぐに使用できません)(2)

    c-MET cDNA Clone (52)

    NM_000245.2

    クローニングベクター cDNA 製品

    In lentiviral vector

    NM_008591.2

    クローニングベクター cDNA 製品

    In lentiviral vector

    XM_006236129.2

    クローニングベクター cDNA 製品

    In lentiviral vector

    NM_001168629.1

    クローニングベクター cDNA 製品

    In lentiviral vector

    c-MET Lysate (11)

      c-MET の背景知識

      Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR protein is produced as a single-chain precursor, and HGF is the only known ligand. Normal HGF/HGFR signaling is essential for embryonic development, tissue repair, or wound healing, whereas aberrantly active HGFR has been strongly implicated in tumorigenesis, particularly in the development of invasive and metastatic phenotypes. HGFR protein is a multifaceted regulator of growth, motility, and invasion, and is normally expressed by cells of epithelial origin. Preclinical studies suggest that targeting aberrant HGFR signaling could be an attractive therapy in cancer.

      c-MET の参考文献

      • McGill GG, et al. (2006) c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem. 281(15): 10365-73.
      • Garcia S, et al. (2007) c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. British journal of cancer. 96(2): 329-35.
      • Socoteanu MP, et al. (2008) c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol. 14(19): 2990-4.
      • Kong DS, et al. (2009) Prognostic significance of c-Met expression in glioblastomas. Cancer. 115(1): 140-8.

      Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.